ReviewCancer treatment reviews2008
Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions.
Review in Cancer treatment reviews, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 4 syntheses or guidelines pooled it, 121 citations in OpenAlex.
- Risk factors for bone metastasis in patients with primary lung cancer: A systematic review.Medicine · 2019Pooled it
- Denosumab versus bisphosphonates in patients with advanced cancers-related bone metastasis: systematic review and meta-analysis of randomized controlled trials.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2018Pooled it
- A meta-analysis survey of appropriate bone turnover markers in the detection of bone metastasis in lung cancer.International journal of clinical oncology · 2017Pooled it
- SEOM guidelines for the treatment of bone metastases from solid tumours.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2012Guideline
- [Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Trial
- Irreversible covalent Bruton's tyrosine kinase inhibitor, TAS5315 versus placebo in rheumatoid arthritis patients with inadequate response to methotrexate: a randomised, double-blind, phase IIa trial.Annals of the rheumatic diseases · 2023Trial
- RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: a prospective study.International journal of molecular sciences · 2013Trial
- Management of Bone-Only Progressive Disease in Metastatic Breast Cancer-A Retrospective Single-Center Analysis.Journal of clinical medicine · 2026Article
- Bilateral Lesions Are Linked to Postoperative Regrowth in Craniofacial Fibrous Dysplasia: Alkaline Phosphatase as a Marker of Clinical Phenotype.Diagnostics (Basel, Switzerland) · 2026Article
- Expert consensus on a multidisciplinary approach for the management of multiple myeloma-related bone disease.Cancer pathogenesis and therapy · 2025Article
- Predicting the Risk for Pathological Fracture in Bone Metastases.Current oncology (Toronto, Ont.) · 2025Review
- Fermented soybean powder containing S-equol alleviates the postmenopausal signs of ovariectomized rats.Food science and biotechnology · 2025Article
- Impact ofNutrients · 2024Article
- Denosumab effect on bone mineral density and urinary-NTX in breast cancer patients receiving aromatase inhibitors.Journal of bone and mineral metabolism · 2023Article
- Application of "omics" sciences to the prediction of bone metastases from breast cancer: State of the art.Journal of bone oncology · 2021Review
- Combinatorial effect of radium-223 and irreversible electroporation on prostate cancer bone metastasis in mice.International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2021Article
- Review
- From latency to overt bone metastasis in breast cancer: potential for treatment and prevention.The Journal of pathology · 2019Review
- Roles of the RANKL-RANK axis in antitumour immunity - implications for therapy.Nature reviews. Clinical oncology · 2018Review
- Bone metabolism markers and angiogenic cytokines as regulators of human hematopoietic stem cell mobilization.Journal of bone and mineral metabolism · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 7 institutions in 4 countries.
Funding
Abstract
backgroundBone metastases are prevalent among patients with advanced solid tumors. Metastatic bone disease alters bone homeostasis, resulting in reduced bone integrity and, consequently, increased skeletal complications. Biochemical markers of bone metabolism may meet an unmet need for useful, noninvasive, and sensitive surrogate information for following patients' skeletal health. MATERIALS AND
methodsData for this review were identified by searches of PubMed, and references from relevant articles using the search terms "bone markers" or individual bone marker nomenclature, "cancer," and "metastases." Abstracts and reports from meetings were included only when they related directly to previously published work. Only papers published in English between 1990 and 2007 were included.
resultsRecent retrospective analyses with bisphosphonates, and particularly with zoledronic acid, have shown significant correlations between biochemical markers of bone metabolism levels and clinical outcomes, especially for bone resorption markers. Clinical results for biochemical markers of bone formation and resorption and other emerging markers of bone metabolism including bone sialoprotein, receptor-activator of nuclear factor-kappaB ligand, osteoprotegerin, and other markers are presented. However, biochemical markers of bone metabolism are not yet an established surrogate endpoint for treatment efficacy.
conclusionsBiochemical markers of bone metabolism may allow physicians to identify which patients with metastatic bone disease are at high risk for skeletal-related events or death and who may be responding to therapy. Prospective randomized clinical trials are underway to further assess the utility of markers of bone metabolism in patients with bone metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.